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Robust biological signaling networks evolved, through gene
duplications, from simple, relatively fragile cascades. Archi-
tectural features such as layered conﬁguration, branching
and modularity, as well as functional characteristics (e.g.,
feedback control circuits), enable fail-safe performance in the
face of internal and external perturbations. These universal
features are exempliﬁed here using the receptor tyrosine
kinase (RTK) family. The RTK module is richly mutated and
overexpressed in human malignancies, and pharmaceutical
interception of its signaling effectively retards growth of
speciﬁc tumors. Therapy-induced interception of RTK-signal-
ing pathways and the common evolvement of drug resistance
are respectively considered here as manifestations of fragility
and plasticityof robust networks. The systems perspectivewe
present views pathologies as hijackers of biological robust-
ness and offers ways for identifying fragile hubs, as well as
strategies to overcome drug resistance.
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Introduction
The ever-burgeoning amount of information on biological
processes and their molecular mechanisms has reached
enormous volumes, especially with the introduction of high-
throughput genomic and proteomic platforms. To remain
meaningful, the ﬂux of reductionist data must be patterned by
novel global concepts, as well as integrated by using
computational and other means. Through uncovering engi-
neering principles and deducing the logics of complex
networks, systems biology offers some attractive solutions.
The aim of this review is to exemplify the systems perspective
in the context of information relay networks and their
relevance to human malignancies. Interested readers are
referred to several recent reviews that analyze complex
signaling networks, as well as their pathological malfunction,
from a systemic perspective (Csete and Doyle, 2004; Kitano,
2004b; Kolch et al, 2005; Hornberg et al, 2006).
Despite the emerging complexity and rich interconnectiv-
ities of signal transduction pathways, CO-OPTION (see Box 1)
of eight generic signaling pathways dominates embryonic
development, normal physiology and many diseases. The list
of major pathways includes G protein-coupled receptors,
nuclear hormone receptors, transforming growth factor beta,
Notch, Janus kinase (JAK), Hedgehog, Wingless-related and
receptor tyrosine kinases (RTKs) (Pires-daSilva and Sommer,
2003). Forseveral reasons, the latterarethe major focus of this
review. First, mutated or overexpressed forms of RTKs are
frequently identiﬁed in human tumors (Blume-Jensen and
Hunter, 2001), and second, pharmaceutical targeting of RTKs,
such as the epidermal growth factor receptor (EGFR) and its
sibling, HER2, can retard tumor growth, primarily in the case
of carcinomas (Yarden and Sliwkowski, 2001).
Signaling by growth factors interacting with RTKs, for
example signal transduction by EGFR, is enormously complex
(for a recent compilation of available data see Oda et al, 2005).
Here we offer two views aimed at simplifying RTK signaling:
an evolutionary approach that tracks the gradual build up of
signaling complexity and the perspective of viral hijackers,
agents that abundantly manipulate network controls for their
pathogenic beneﬁt. Following a discussion of biological
robustness, with an emphasis on control circuits, we discuss
systems vulnerability in the context of cancer therapeutics.
Last, we review the evolvement of secondary resistance to
RTK-targeted cancer drugs, and present acquired resistance
to signal transduction pharmaceuticals as a demonstration
of systems adaptability.
RTKs: a primer
Shared structural landmarks
To precisely coordinate and integrate cellular decisions such
as proliferation, differentiation and apoptosis, metazoans
developed a set of information relay systems, including the
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www.molecularsystemsbiology.comgroup of RTKs (Blume-Jensen and Hunter, 2001). There are 58
known RTKs in mammals, and they are distributed in 20
subfamilies. Characteristically, an RTK molecule is divided
into two parts by a single transmembrane domain (Figure 1):
the extracellular domains of RTKs exhibit remarkable struc-
tural variation. On the other hand, the cytoplasmic domain
comprises primarily a well-conserved bilobular protein tyr-
osine kinase region. The N-terminal lobe of the kinase domain
comprises beta-strands and a single alpha-helix, whereas the
C-terminal lobe is composed mainly of alpha-helices, which
nest ATP in a cleft deﬁned by the two lobes (Hubbard and Till,
2000).
Shared functional features
Signaling pathways downstream of RTKs are largely shared,
although some pathways, for example IRS activation by the
insulin receptor family, are subfamily speciﬁc. Nevertheless,
each RTK is uniquely coupled to an ensemble of signaling
pathways whose identity and relative strength of activation
constitute an enormous combinatorial complexity, which can
be approached by high-throughput experimental strategies
(Schulze et al, 2005; Zhang et al, 2005; Jones et al, 2006). Both
the extracellular and the intracellular domains of RTKs are
maintained in autoinhibited, locked conformations, which are
released when a ligand binds. Ligand-induced dimerization of
RTKs is responsible for instigating these alterations. For
example, according to the crystal structures of EGFR/ERBB-1
(Garrett et al, 2002; Ogiso et al, 2002), prior to ligand binding a
dimerization loop imposes an intramolecular ‘tethered’ con-
formation. Upon ligand binding, a major conformational
change detaches the intramolecular tether and stabilizes the
‘active’ form inwhich the unmasked loop projects outwards to
mediate dimerization. Ectodomain transition to the ligand-
bound, active conformation is relayed across the plasma
membrane and culminates in the activation of the kinase
domain. According to a recent study, the C-lobe of one kinase
domain is juxtaposed next to the N-lobe of the other (Zhang
et al, 2006). Hence, the C-lobe of one RTK serves as the
activator of the other kinase domain.
Involvement of RTKs in human cancer
The pivotal role of RTKs as regulators of cellular decisions is
apparent when acknowledging that these mitogenic receptors
are encoded by the largest group of oncogenes sharing
structural homology (Blume-Jensen and Hunter, 2001), and
asmanyasB30%oftheRTKsarerepeatedlyfoundmutatedor
overexpressed in different malignancies. Examples of RTKs
involvedin human cancer (Figure 1) include RET, a coreceptor
forglial cell line-derived neurotrophic factors,the subfamilyof
the hepatocyte growth factor receptors (HGF-R/c-MET), c-KIT,
the receptor for the stem cell factor, EGFRand HER2. The most
common thyroid tumors are driven by chromosomal rearran-
gements, which fuse the kinase domain of RET to a variety of
protein dimerization domains. In addition to somatic gene
fusions, germline mutations are involved in three familial
tumor syndromes: multiple endocrine neoplasia 2A and 2B,
and familial medullary thyroid carcinoma (FMTC). Most
MEN2A and FMTC mutations affect conserved extracellular
cysteines, causing constitutive receptor dimerization (Santoro
etal,1995).MEN2Biscausedbyarecurrentmutationreplacing
a conserved methionine within the kinase domain and altering
substrate selectivity of RET (Bocciardi et al, 1997). Another
mechanism of oncogenic activation is exempliﬁed by c-KIT.
Several oncogenic mutations found in gastrointestinal stromal
tumors affect the catalytic region or the juxtamembrane
domain of this RTK, which participate in autophosphorylation
and in inhibition of kinase activity (Hirota et al, 1998).
Excessive EGFR/ERBB signaling, arising from receptor
overexpression, mutations or AUTOCRINE stimulation, is a
hallmarkofawidevarietyofsolidtumors.Ampliﬁcationofthe
ERBB-2/HER2 gene can be found in 20–30% of metastatic
breast lesions (Slamon et al, 1987) and high EGFR expression
was found in small fractions of several types of carcinoma
(e.g., head and neck cancer and brain tumors; Ekstrand et al,
1991). Somatically acquired EGFR mutations in lung cancer
activate receptor phosphorylation and they predict signiﬁcant
clinical responses to kinase inhibitors (Lynch et al, 2004). All
mutations are restricted to the tyrosine kinase domain of
EGFR. Similar to EGFR mutations, a kinase-mutated HER2/
ERBB-2 was shown to be more potent than wild-type HER2
Box 1 Glossary
Antibody-dependent cell-mediated cytotoxicity (ADCC):
A mechanism of cell-mediated immunity whereby an effector cell
of the immune system (usually a natural killer cell) lyses a target cell
that has been bound by speciﬁc antibodies.
Autocrine loop: Self-production of a stimulatory activity, resulting in
autonomous cellular function. For example, coexpression of a
mitogenic growth factor and the cognate RTK in the same cancer cell.
Bistability: The ability of a system to transit between two states,
‘On’ and ‘Off’, with no, or little, intermediary states.
Co-option: Reusing existing genetic components, metabolic
reactionsorsignalingmodulesindiversebiologicalsystems,suchasin
development of body plans, evolution of transcription factors or
construction of signaling networks.
Robustness: An inherent property of a system to maintain normal
performance despite external and internal perturbations.
Sub-functionalization: Concurrent partial loss of functions of the
protein products of duplicated genes, such that collaboration between
the respective gene products reconstitutes the full set of sub-functions
characterizing the original ancestor.
Random network: A uniform (democratic) network, where most
nodes have roughly the same number of links.
Scale-free network: A non-uniform network whose connectivity
(number of nodes with a given degree) follows a power law. Scale-free
networks are characterized by coexistence of nodes of widely different
degrees (scales) (Barbasi and Alberts, 1999), which means that there
are nodes with 1–2 links alongside with major hubs.
Evolvability: The capacity of an organism or a biological system to
generate heritable new phenotypes.
Targeted therapy: A relatively new ﬁeld of pharmacology focusing
on drugs tailored to inhibit speciﬁc molecules, such as enzymes and
receptors, thereby avoiding adverse clinical effects, which are usually
associated with the application of broad-speciﬁcity regimens.
Network hub: A network node having a relatively large number of
links to other nodes within its network.
Network motif: A pattern of interaction that recurs in cellular
networks signiﬁcantly more often than in randomized networks.
Composite feedback loop: A composite two-arm loop in which a
protein P, that slowly induces (at the transcriptional level) a gene g,
which upon translation rapidly regulates protein P at the level of
protein–protein interactions.
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inducing invasiveness and tumorigenicity (Wang et al, 2006).
The enigma of pseudo-RTKs and the ligandless
receptor, HER2
Several RTKs (e.g., RYK/VIK and KLG) belong to a group of
inactive kinases, which have been termed pseudokinases
(Boudeau et al, 2006). The best-characterized pseudo-RTK is
ERBB-3. Unlike other RTKs, neither ERBB-3 nor HER2 can
undergo direct activation by a ligand; whereas ERBB-3’s
intrinsic kinase activity is impaired (Guy et al, 1994), no
known soluble ligand binds to and activates HER2 (Klapper
et al, 1999). Hence, these non-autonomous receptors must
heterodimerize with each other, as well as with other RTKs, to
generaterelativelypotentsignalsforcellgrowth.AllfourERBB
proteins evolved from a single precursor RTK represented by
theworm’sLET-23 (Aroian et al, 1990). Whynon-autonomous
RTKs were preserved in the course of evolution is an open
question, which we address below from an evolutionary point
of view that highlights the relevance of a systems biology
approach to RTK signaling.
The evolution of RTK-signaling networks
According to one interpretation, the HER2–ERBB3 enigma is
due to accidental receptor inactivation events that occurred in
the course of metazoan evolution. An alternative explanation
considersthegenerationofnon-autonomous receptorssuchas
HER2/ERBB-2 and ERBB-3 as a by-product of several evolu-
tionary trends that transformed linear signaling cascades
into layered, richly interconnected networks (see Figure 2).
Conceivably,theconversionfromlineartonetworkarchitecture
assisted generation of both novel body plans and new cell
lineages in metazoans. Furthermore, the evolutionary trends
we review below and the ensuing establishment of networks
conferred both ROBUSTNESS (Stelling et al,2 0 0 4 )a n d
EVOLVABILITY (Kirschner and Gerhart, 1998), while the
co-optionofrelativelyfewpathwaysavoidedinﬂatedexpansion
of primordial genomes.
Need for increased control and capacity of
signaling pathways—from unicellular to
multicellular organisms
Unicellularorganismsareinclosecontactwiththeirenvironment
and directly respond to nutrients, vitamins, radiation, radicals
and, in some cases, also mating factors. Because these
external stimuli often permeate the cell membrane to interact
with cytoplasmic or nuclear targets, generic multilayered
signaling cascades are rare in unicellular organisms. Such
fundamental cascades widely evolved in bilaterians, multi-
cellular organisms presenting a body cavity and bilateral
symmetry. However, the more sophisticated RTK cascades are
represented almost exclusively in metazoans (Shiu and Li,
2004). One enlightening exception to this observation is seen
for the unicellular organism closest to metazoans, a ﬂagella-
containing group of protists called Choanoﬂagellates
(Pires-daSilva and Sommer, 2003). These protists are recog-
nized as being closest to prospective unicellular ancestors of
metazoans and are ‘between’ fungi and multicellular animals.
Evidence has accumulated that Choanoﬂagellates already
invented generic signaling cascades, raising the possibility that
multicellularity evolvement necessitated the establishment
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Figure1 RTKsassociatedwith cancer.The structures ofseveral cancer-relevant RTKsare schematically presented, including conserved domains andinformation on
involvement in malignancies. The horizontal gray bar represents the plasma membrane. VEGFR, vascular endothelial growth factor receptor; HGFR, hepatocyte growth
factor receptor; RET, rearranged during transfection.
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a Choanoﬂagellate, provisionally contains one or more
representatives of seven subfamilies of RTKs (genome.
jgi-psf.org/Monbr1). In conclusion, tyrosine kinases may
beviewed as the providenceof metazoans andtheir immediate
‘unicellular predecessor’.
Gene fusion—from simple proteins to multidomain
proteins
The availability of detailed whole-genome sequence data, as
well as interspecies comparisons, indicated that vertebrate
proteins are characteristically larger and contain more
structurally recognizable domains when compared with their
orthologs in Caenorhabditis elegans and Drosophila.A
common hypothesis argues that the large modular structures
of mammalian proteins involved in information relay systems
are the outcome of repeated gene fusion events, combining
diverse functions in one protein. RTKs provide an interesting
example of gene fusion and ligand–receptor coevolution (for
an example of the evolution of the neurotrophin family and
TRK receptors see Lanave et al, 2007). The origin of their
divergent extracellular ligand-binding domains is thought to
represent a primordial binding protein, specializing in
recognition of extracellular ligands or nutrients. Conceivably,
by means of chromosomal rearrangement and gene fusion,
this domain likely fused to a transmembrane protein whose
hydrophobic domain conferred anchorage to the cell surface,
whereas the cytoplasmic tail enabled internalization of the
extracellular ligand. Apparently, a second gene fusion event
extended the cytoplasmic domain by adding the catalytic
region of a cytoplasmic tyrosine kinase (CTK) similar to the
current version of a SRC family kinase. The resulting
archetypal RTK acquired an ability to stimulate auto- and
trans-phosphorylation in response to ligand binding, while
harnessing the cargo internalization capability for effective
desensitization of signaling.
The need for versatility and control—from nuclear
hormone receptors to receptors for polypeptide
factors
Figure 2 shows the number of RTKs per phylum throughout
evolution. A trend of RTK expansion paralleled evolution of
metazoans and peaked in vertebrates. Notably, no comparable
trend impacted the superfamily of nuclear hormone receptors
(NHRs). Another reﬂection of the trend leading to expanded
signaling by polypeptide growth factors is exhibited by the
numberofRTKligands,whichincreasedinthecaseoftheERBB
family from one in worms to 11 ligands and many isoforms in
human. Conceivably, the transition from steroids, retinoic acid
and other NHR ligands, whose synthesis is cumbersome and
transcriptional action direct, to polypeptide ligands, conferred
several advantages: polypeptide growth factors are better
regulated at the level of synthesis, their multiple binding
proteins tightly control availability after synthesis and their
actions at the membrane/cytoplasm and at the level of gene
expression contrast with the mostly genomic action of NHRs.
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Figure 2 The evolution and expansion of RTK signaling. The number of kinases and MAPKs in several representative species are listed for vertebrates and for key
invertebrate phyla, or other eukaryotes with whole-genome data. The number of CTKs (cytoplasmic tyrosine kinases) and RTKs were derived from published total
tyrosine kinase counts, except where marked and noted below, as were counts of EGFRs/ErbB (EGFRs) and MAPKs. The ratio of vertebrate to average invertebrate
counts of each protein category was calculated, as weighted for total proteome size. Asterisks indicate that the RTK, EGFR and MAPK ratios show the most signiﬁcant
departures from a ratio of one, each with a P-value o0.0001. The counts were derived from the respective published genomes and the following references:
urochordate (Satou et al, 2003); sea urchin (Bradham et al, 2006); fruit ﬂy (Morrison et al, 2000); slime mold (Goldberg et al, 2006); a choanoﬂagellate [assembly
version 1.0 (genome.jgi-psf.org/Monbr1/)] and (Shiu and Li, 2004). The notable departures from published counts are as follows: w the 22 Caenorhabditis elegans
CTKsdonotinclude37genesoftheexpanded38geneFERfamily,nor19ofthe21paralogsofthenematodespeciﬁcexpansionofKin-9andKin-16genes;ww,thetwo
EGFRs in Ciona intetinalis reﬂect a duplication event that took place after urochordates split and diverged from the vertebrate lineage.
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individual genes to gene families
An important feature of the evolution of signaling systems is the
occurrence of gene duplications and subsequent protein se-
quence divergence. Gene duplication events frequently occur in
the course of evolution at a background rate of 0.01 duplications
per gene in million years (Lynch and Conery, 2000), and in
punctatedlarge-scaleevents. Although themajorityofduplicated
genes are either lost or become pseudogenes, in many cases the
ensuing genes are retained in the genome. The most notable
retaining mechanism is SUB-FUNCTIONALIZATION,ap r o c e s s
that partially inactivates sub-functions and promotes collabora-
tions between duplicated gene products.
Expanding the tyrosine kinome and the RTK family
The tyrosine kinase protein complement of the vertebrate
kinome is larger than that of invertebrate kinomes (Figure 2),
and a core increase of RTKs, rather than CTKs, accounts for the
larger kinomes of vertebrates (Shiu and Li, 2004). Thus, the
kinomes of nematodes, ﬂies, sea urchins and urochordates
contain, respectively, 12, 18, 19 and 16 RTKs (Tan and Kim,
1999; Morrison et al, 2000; Bradham et al, 2006), but the
kinomes of mammals contain 58 RTKs. Of these, 14 represent a
speciﬁc expansion of the Ephrin receptor (EPHR) subfamily,
which is presaged by six receptors in the kinome of the basal
chordate Ciona intestinalis (Leveugle et al, 2004). Whether or
not the chordate-speciﬁc EPHR expansion is discounted, the
RTKsrepresentatwo-tofourfoldincreasefrominvertebratesto
vertebrates,whichisconsistentwithgenomeduplicationatthe
root of vertebrate evolution. Indeed, the later of the two bursts
of gene duplications in metazoans has been dated to 400
millionyearsago(MiyataandSuga,2001).Thus,atrendofRTK
expansion peaked in vertebrates with duplications or
quadruplications, and for nearlyevery one of the RTK subfamilies,
the human paralogs are present in a two- to fourfold excess over
their protostome, or invertebrate deuterostome, orthologs.
Evolution of subtype I RTKs (ERBB) as an example
The cast of mammalian ERBB proteins ﬁts into the presumed
route of RTK evolution. In line with whole-genome quad-
ruplication, the family is represented by a single ligand–re-
ceptor pair in C. elegans, and the mammalian family includes
four members, which were likely preceded by two ancestors,
an ERBB-1/2 precursor and an ERBB-3/4 ancestor, as well as
two respective groups of ligands: EGF-like growth factors and
the neuregulins (Stein and Staros, 2000). Moreover, the family
presents an example of sub-functionalization: ERBB-2/HER2
and ERBB-3 are likely the products of a coordinated gene
duplication, which complementarily denied a ligand from
HER2 and inactivated the kinase function of ERBB-3, thereby
promoting receptor collaboration.
From linear cascades to scale-free signaling
networks
Similar to the ERBB family, other RTKs and ligands underwent
expansion through gene duplications. Beyond the numerical
growth and conversion of individual RTKs to distinct families,
gene duplication greatly impacted the topology of evolving
RTK-signaling networks: it has been argued that upon
duplication highly connected proteins retain interactions with
both gene products, which creates networks rich in highly
connected nodes (Rzhetsky and Gomez, 2001; Pastor-Satorras
et al, 2003). As a result, earlier and more conserved nodes
evolve into richly linked nodes, namely NETWORK HUBS.
Further, mathematical analysis of network’s growth processes
has demonstrated that newly added nodes prefer to connect to
nodes that already are well connected (so-called ‘preferential
attachment’; Barabasi and Oltavi, 2004). This growth process
proposes an explanation to yet another trend in the evolution
of signaling systems, one that transforms RANDOM NET-
WORKS into the hub-enriched topology called SCALE-FREE
NETWORK. In conclusion, the trendsand growth processeswe
reviewed gradually transformed simple, relatively fragile,
linear arrangements of ligands–RTK–effectors into layered
networkconﬁgurations,whichgreatlyenhancereproducibility
and reliability of signal transfer (Figure 3).
How do RTK networks maintain functional
robustness?
The above-described collection of evolutionary trends per-
mitted vertebrates to evolve progressively more robust
signaling networks, while maintaining the overall gene
number of their immediate predecessors. One important
advantage of networks of RTKs and other signaling systems
is theirability to maintain output reproducibility, despite input
variation and inherently stochastic signal processing (Kholo-
denko,2006).Severalcriticaldesignfeaturesimpartfunctional
robustness (see Box 2). Structurally, robust systems share a
bow-tie structure in which a core process receives diverse
inputs and reproducibly integrates them to generate a myriad
of outputs. Typically, the bow-tie structure comprises several
modules, which are partially redundant. Module diversity and
redundancy allow compensatory functioning in case of
component’s failure. Further, modularity enables reutilization
of genetic circuits in different biological settings, adaptation to
rapidly changing environments (Alon, 2003), as well as the
generation of new cell lineages (Tautz, 2000; Alon, 2006). In
addition to architectural features, robust networks share
functional attributes like dynamic switching of signals into
alternative pathways (plasticity), and the ability to transitorily
accumulate protein aberrations without signiﬁcantly altering
network’s outcome (tolerance).
Systems control: the power of feedback loops
Perhaps the main functional feature that accounts for
robustness comprises systems control, namely a collection of
feedback loops, which quantitatively relate network’s output
to a varying input (Freeman, 2000). Positive feedback loops
enhance the amplitude and prolong the active state to convey
robustness. Further, such loops can generate an irreversible
biochemical response from a transient growth factor stimulus
(Xiong and Ferrell, 2003). One important mechanism of
positive feedback is based on autocrine loops in which RTK
ligands are produced following receptor activation. Likewise,
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which systems attain robustness, as they comprise a major
stabilizing role in complex circuits (Smolen et al, 2000). From
an engineering point of view, denser feedback circuitries
characterize rapidly responding elements such as the immedi-
ate-early genes (IEGs) regulating AP-1 activity (Sassone-Corsi
et al, 1988), and nuclear or cytoplasmic hubs, such as c-Myc,
MAPK and p53. The large spectrum of RTK’s feedback control
mechanisms may be divided into two types: feedback loops
comprising pre-existing components, which undergo post-
translational modiﬁcations to enable immediate tuning of the
output (Dikic and Giordano, 2003; Santos et al, 2007), as well
asfeedbackloopsrelying onnewlysynthesizedcomponents,a
collection of IEGs and delayed-early genes (DEGs; Table I),
which control response time and increase network’s robust-
ness. Because mRNA synthesis and subsequent protein
synthesis and post-translational modiﬁcations/translocations
may take 15–90min, this time window deﬁnes the major
temporal domain of RTK signaling (Figure 4).
Pre-existing negative feedback regulators of RTKs
Ubiquitin ligases,proteinkinases and phosphatases,aswellas
adaptor proteins, play major roles in immediate regulation of
RTK signals (Dikic and Giordano, 2003). c-CBL is a phospho-
tyrosine-activated mammalian E3 ubiquitin ligase that criti-
cally instigates signal attenuation by conjugating ubiquitin to
activated RTKs, thereby promoting receptor endocytosis and
lysosomal degradation (Marmor and Yarden, 2004). A second
example, which seems to be a recurrent circuit (NETWORK
MOTIF) in signaling pathways, includes an inhibitory phos-
phorylation connecting a downstream signaling component
with itsupstreamactivatingenzyme, asinthecase oftheERK/
MPAK-signaling cascade where both MAPKKK (RAF) and
MAPKK (MEK) are feedback regulated by negative edges from
the downstream MAPK (ERK) (Santos et al, 2007).
Box 2 Architectural and functional features shared by robust
biological and technological systems
Bow-tie structure: An hourglass conﬁguration linking input and
output layers through a core circuitry entailing a complex, but
reproducible, signal-processing module. In this structure the core
circuitry is a point of fragility.
Modularity: Division into partially autonomous sub-systems built to
contain damage and diversify signal processing.
Functional overlap (redundancy): Coexistence of functionally
similar modules and individual components, thus offering alternate
routing of signals in case of component/module inactivation.
System controls: Linked circuitries ensuring dynamic and
bidirectional coupling of output to input. Both negative and positive
feedback loops exist and they permit ampliﬁcation of weak signals,
restraining of overt signals, as well as noise dampening.
Plasticity (pathway switching): Rich branching and functional
ﬂexibility allowing dynamic switching of signals into alternative
pathways, to achieve nearly identical outcomes.
Tolerance: Network’s ability to transitorily accumulate structural and
functional aberrations without signiﬁcantly altering the outcome of
incoming signals. The molecular basis of tolerance includes chaperone
proteinsthatrefoldmildlymutatedclientproteins(Sangsteretal,2004).
Uncoupled cascades
Signaling network
Primordial cascade
Option A
Option B
Figure 3 From a vertical RTK cascade to a signaling network. The boxed cascade (left) represents an invertebrate primordial signaling pathway comprising a growth
factor, an RTK and a signaling cascade culminating in regulation of gene expression (horizontal arrows). Two RTK expansion scenarios are presented. According to
Option A, two events of RTK duplication generate four vertical cascades that gradually diverge, but they remain isolated from each other. According Option B, the four
cascades richly interact and ultimately establish a layered signaling network. The lines of evidence we describe herein propose that the evolution of RTKs in vertebrates
preferred Option B, because it imparts robustness and guarantees output reproducibility.
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Transcriptional negative feedback regulation of RTKs ﬁrst
emerged from genetic screens of lower organisms (Casci and
Freeman, 1999). For instance, growth factor activation of the
ERK/MAPK-signalingpathwayinmammaliancellsculminatesin
ERK translocation to the nucleus, to activate transcriptional
complexes. Along with transcriptional repressors, and other
proteins (Table I), a broad group of dual-speciﬁcity phosphatases
(DUSPs, also known as MKPs) are transcriptionally induced by
MAPK activity to feedback inhibit the function of MAPKs (Amit
etal,2007).AsimilarexampleentailsSproutyproteins,whichare
newly induced by growth factors and antagonize RTK signaling.
Similarly, the ﬁbroblasts-derived growth factor receptor (FGFR)
inhibitor, SEF, is newly synthesized in response to FGF (Tsang
and Dawid, 2004). In another example, cytokine signaling
through the JAK/STAT-signaling pathway is feedback inhibited
by the suppressor of cytokine signaling (SOCS1), which targets
for proteasomal degradation several proteins of the JAK/STAT
pathway. Interestingly, the inducible adaptor protein ERRFI1/
MIG6/RALTspeciﬁcally inhibits ERBB proteins by reducing their
autophosphorylation(Ferbyetal,2006),whereasNFkBsignaling
is feedback inhibited by the combined ubiquitinylation and
deubiquitinylation activity of the TNFAIP3/A20 protein (Wertz
et al, 2004).
P
MAPK
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TF1
P
P
P
TF1 mRNA (IEG)
TF1
mRNA (DEG)
Transcriptional repressors
(e.g., NAB2)
RNA-binding  proteins
(e.g., ZFP36)
Phosphatases
(e.g., MAPK phosphatases)
0
2 min
10 min
40 min
60 min
The
window
of activity
(I)
x
A R
t
(II)
x
A
(III)
x
A
R ZZ Z
TF2
Figure 4 Dense feedback circuits deﬁne the window of RTK activity. The timeline (left) indicates the window of growth factor (GF) activity following binding to an RTK.
Receptorphosphorylation(denotedbyP)isfollowedbysequentialactivationofakinasecascadeculminatinginMAPKactivationthroughdoublephosphorylation.MAPK
translocationtothenucleusenablesdirectphopshorylationoftranscriptionfactors(TF1),whichactivatetranscriptionofIEGs(e.g.,theAP-1componentsJUNandFOS).
IEGsregulate asecond wave of transcription. TheDEGs encode abroad range ofproteins,including negative regulators. The signaling arm (orange line) isregulated at
the tier of MAPKs by the group of DUSPs, whereas transcription is regulated by the induction of transcriptional repressors (blue line; e.g. KLF2 and ATF3) and RNA-
bindingproteins(greenline;e.g.ZFP-36),whichregulatemRNAstability.Collectively,thesefeedbackloopsshutthewindowofRTKsignaling.Boxedarethreediagrams
ofmixedfeedbackcircuitspotentiallyformingstableexpressionproﬁlesoflate-inducedgenes(e.g.,geneZ;solidlinesrepresenttranscriptionaledges,andadashedline
indicates protein–protein interactions). I: Transcription factor x immediately activates a transcriptional activator A and slowly activates, after an intrinsic delay t,a
transcriptional repressor R.This module enables pulsedinductionof atarget gene Z.II:Anegativefeedback loop comprisinga transcription activatorx,whoseactivity is
attenuated by its target gene A, resulting in a deﬁned window of expression of gene Z. III, A negative feedback loop comprising a repressor R, which is connected by a
transcriptional edge to the immediate-early transcriptional activator A, thus deﬁning the temporal activity of A by the transcription of both R and the output gene Z.
Table I IEGs and DEGs downstream of RTKs
Gene symbol Time of peak
expression B
(mRNA, min)
Transcription
complex/signaling
pathway
IEG
FOS
a 10–20 AP1
JUN
a 10–20 AP1
EGR1 30 EGR
DEG
KLF2 40–60 AP1, NFKB
KLF6 40–60 AP1, NFKB
ZFP36 40 ARE mRNAs
stability
JUNB 40–60 AP1
FOSL1 60–120 AP1
FOSL2 60 AP1
NAB2 120 EGR
MAFF 120 AP1, NF-E2
EGR3 40–60 EGR
DUSPs 30–120 MAPKs
ATF3 40–60 NFKB, AP1
CREM 60–120 CREB
NFKBIA (IKBa) 30 NFKB
NFKBIE (IKBe) 90–120 NFKB
Abbreviations: DEG, delayed-early gene; IEG, immediate-early gene; RTK,
receptor tyrosine kinase.
aHomologous to a retroviral oncogene.
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An important machinery of feedback control is condensed at the
level of mRNA regulation, a network layer enriched with hub
elements (Figure 5). Early observations reported on ‘super-
induction’ of IEG products, upon cell treatment with growth
factors, especially in the presence of protein synthesis inhibitors
(Lau and Nathans, 1987). This phenomenon has been attributed
to inducible proteins that regulate the rates of both mRNA
synthesis and mRNA degradation. Consistent with ‘super-
induction’, large-scale analysis of regulatory pathways in yeast
identiﬁed a COMPOSITE FEEDBACK LOOP as a recurring motif
(Yeger-Lotem et al, 2004). This two-arm loop comprises a protein
P that slowly induces (at the transcription level) several target
genes, including a gene whose translation product rapidly
regulates protein P through protein–protein interactions.
The alternative, a combination of two slow arms, would cause
oscillations, which explains the stabilizing role for composite
feedback loops in RTK networks. Three previously described
general scenarios of composite feedback loops (Alon, 2006) are
exempliﬁed below in the context of RTKs (Table I; Figure 4).
Type I
Rapid induction of a transcription activator and slow
transcription of a transcription repressor, allowing a tempo-
rally deﬁned window of activity. Examples include FOSL1 and
JUNB, which are induced in a delayed manner compared with
the rapid induction of the AP1 components FOS and JUN.
Type II
This autoregulatory loop utilizes the lag between transcription
and translation. For example, newly synthesized FOS binds to
elements within its own promoter to inhibit transcription of
the FOS mRNA (Sassone-Corsi et al, 1988).
Type III
This feedback loop comprises a transcriptional activator
regulating its own transcription repressor. For example, the
TCF transcription factors are feedback regulated by their own
transcriptional products, namely the Id proteins (Yates et al,
1999).
Viruses and diseases are master
manipulators of robust RTK networks
Although many robust cellular programs maintain stable and
regulated function under a broad range of perturbations, as
will be described below, certain pathologies and various
viruses selected vulnerable network’s nodes, as well as
features of systems control, thereby taking advantage of the
intrinsic robustness of the cellular program for their own
purposes.
DNA and RNA viruses
Certain types of oncogenic DNA and RNA viruses devised
strategies to harness cellular programs. Interestingly, while
retroviraloncogenesaretheproductsoftransductionofcellular
genes, oncogenes of DNA viruses represent primarily novel
designs. Nevertheless, DNA and RNA viruses share some
cellular targets. One example relates to the CTK SRC, a
truncated form of which is encoded by the Rous sarcoma
virus, and the cellular form of which is bound and activated by
themiddleTantigenofaDNAvirus,Polyoma(Courtneidgeand
TNF
NGF
EGF
TNFR
NGF CREB EGR1 NAB2 90 min
Window
of activity
LPS
B       F N F N T S P L
NFKBIA
120 min NF   B
EGF MAPK DUSP 30 min
NF   B 20 min TNF NFKBIA
(I   B   )
(I   B   )
Figure 5 Examples of composite feedback loops deﬁning windows of activity of various extracellular ligands. Ligand–receptor interactions (left) are followed by rapid
activation of a signaling protein (e.g., MAPK), which induces in a delayed manner (see clock) an inhibitory protein (e.g., DUSP; solid lines deﬁne transcriptional edges
and dashed lines represent protein–protein interactions). The coupling of a slow transcriptional arm and a rapid protein interaction arm sets the interval of window
opening(B30mininthecaseforEGFandMAPK).Alonger(B90min)windowoftranscriptional activityisachievedwhenarelayoftwotranscriptionalprocesses(e.g.,
EGR1 and NAB2) is needed to produce the negative regulator (NAB2) downstream of the nerve growth factor (NGF). NFkB serves as a target of several growth factors
and cytokines. Two examples of pulsed NFkB activation are presented: a short window of activity is generated by the circuit of the negative regulator IKBalpha, which
inhibits NFkB activity downstream of the TNFR. A relatively long (B120min) activation of NFkB is induced by lipopolysacharide (LPS): an initial weak activation of
NFkB produces a feed-forward element (TNF) and the second is a strong activation of NFkB by TNF, which activates the transcription of the inhibitor IkBalpha.
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erythroblastosis virus encodes a truncated version of EGFR
(Downwardetal,1984),whereasmanyligandsofthisreceptor,
andofotherERBBfamilymembers,areencodedbypoxviruses
(Tzahar et al, 1998). By encoding (or by inducing) ligands, or
active forms of either RTKs or their downstream targets,
pathogenic virusesmanipulatean importantfeature of systems
control. RTKs, transcription factors and other control modules,
are able to oscillate between two or more states. State
transitions are normally controlled by switch-like mechanisms
involving both positive and negative feedback loops, but
viruses often lock such systems in the active state (Hunter,
2000). It is worth noting that oncogenic viruses disproportion-
ally lock speciﬁc signaling hubs, such as the RAS-RAFand the
PI3K–AKT nodes (Rapp et al, 2006), and these very same hubs
are frequently mutated in human tumors (Hanahan and
Weinberg, 2000). Conceivably, this viral preference reﬂects
the scale-free nature of cellular signaling networks, as well as
the inherent vulnerability of major hubs developed along the
transition from uniform to scale-free systems (Barabasi and
Oltavi,2004).Alongthisvein,hubsindependentlyidentiﬁedby
both viruses and cancer mutations may serve as targets for
effective therapeutic interventions (see below).
Cancer tactics that circumvent systems control
Malignant growth associates with several traits common to
most types of human tumors (Hanahan and Weinberg, 2000).
Some traits, for example those related to apoptosis, angiogen-
esis and metastasis, are directly regulated by RTKs. For
example, self-sufﬁciency in growth signals often results from
autocrine loops such as those involving the transforming
growth factor alpha and HB-EGF, whose synthesis and
cleavage at the cell surface require activation of MAPK and
proteinases of the ADAM family (Schafer et al, 2004),
respectively. Acquisition of growth autonomy by tumor cells
may be imparted by mutationally activated RTKs (Blume-
Jensen and Hunter, 2001), as well as by mutations affecting a
relatively small group of signaling molecules. For instance,
oncogenic mutations impinge on components regulating
either the RAS-MAPK pathway, primarily mutations in RAS
(Bos, 1989) and B-RAF (Davies et al, 2002), or the PI3K–AKT/
PKB pathway, including mutations in the catalytic subunit of
PI3K (Samuels et al, 2004), as well as loss of the PTEN tumor
suppressor.
Along with mutational activation of RTK signaling, high-
throughput analyses reveal that loss of negative feedback
loops characterizes solid tumors (Amit et al, 2007). For
example, EGF upregulates a delayed burst of negative
regulators, including MAPK phosphatases (e.g., DUSP6 and
DUSP7), transcription repressors (e.g., KLF2 and FOSL1) and
RNA-binding proteins (e.g., ZFP-36 and TIAL1), which act
upon MAPK and components of the AP1 complex to down-
regulate their proliferation-promoting activity. Particularly
interesting are late-induced proteins, like ZFP-36, able to bind
AU-rich elements (AREs) in 30 untranslated regions of mRNAs
(Carballo et al, 1998). A large number of the RTK-induced
genes,includingc-FOS,containAU-richsequenceswithin their
30 untranslated regions.InterestinglyZFP-36 cooperateswith a
micro-RNA (miR16) in mRNA degradation (Jing et al, 2005),
raising the possibility that micro-RNAs play essential roles in
the feedback regulation of RTK signaling. Interestingly, a
subset of the late-induced RNA- and DNA-binding proteins is
constitutivelydownregulatedinalargevarietyofsolidtumors,
and diminished expression predicts shortersurvival ofovarian
and prostate cancer patients (Amit et al, 2007). In striking
similarity, a partially overlapping set of negative feedback
loops is upregulated upon treatment of thyrocytes with the
thyroid-stimulating hormone (TSH; van Staveren et al, 2006).
Moreover, some regulators were found to be downregulated in
adenomas, suggesting a loss of negative feedback control in
the tumors. In conclusion, in similarity to oncogenic viruses,
cancer-promoting mutations lock RTK signaling in the active
state by elevating forward processes, as well as by inhibiting
negative feedback loops.
Network’s fragility: the basis of
RTK-targeted cancer therapy
According to a widely accepted model, originally applied to
colorectal cancer (Vogelstein and Kinzler, 2004), stepwise
accumulation of mutations in proto-oncogenes, tumor sup-
pressor genes, as well as genes encoding DNA-repair proteins,
drivescancerprogressionfromahyperplastic,benignlesion to
a metastasizing tumor. Cataloging the set of oncogenic
mutations of speciﬁc carcinomas already permits clinicians
to intercept tumorigenic mechanisms by using novel targeted
therapies. Unlike cytotoxic strategies, which are relatively
non-selective and inadvertently increase intratumoral hetero-
geneity, TARGETED THERAPY addresses homogeneously
distributed lesions. From a systemic perspective, successful
application of cancer therapy necessitates identiﬁcation of
fragile aspects of tumors’ robustness, an emergent property
acquired throughout cancer progression. The Highly Opti-
mized Theory (HOT), originally applied to technological
systems, argues that evolvable systems are robust against
common perturbations, but they show fragility against
unusual ones (Carlson and Doyle, 2000). When applied to
RTK networks, HOT predicts resistance to interceptions of
individual components (single-agent therapy), but fragility in
the faceof simultaneous perturbations (combination therapy),
a rarely occurring event for evolution-trained networks.
Another type of fragility derives from the exaggerated reliance
of scale-free systems on very few hubs. Indeed, the tradeoff of
tumors’ robustness is ‘addiction’ to speciﬁc oncogenes
(Weinstein, 2002), as well as to nutrients and blood supply.
Hence, drug-mediated blockade of speciﬁc oncogenes, as well
as deprivation of blood supply, may retard tumor growth.
Frequent genetic aberrations in epithelial tumors, as well as
roles in cell proliferation, metastasis and angiogenesis, make
RTK signaling one of the most attractive target for anticancer
therapies (Baselga, 2006). In the following sections we review
clinically approved and experimental RTK-targeting drugs (see
Table II) from a systems biology perspective.
Monoclonal antibodies
Humanized, chimerized or completely human antibodies to
RTKs are already in clinical use. They include an antibody to
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treatment, and two anti-EGFR/ERBB-1 antibodies (cetuximab
and panitumumab), approved for treatment of colorectal
cancer and head and neck cancer. Likewise, an antibody to
the vascular endothelial growth factor (VEGF), Bevacizumab,
has been approved for treatment of colorectal cancer (Ferrara,
2005), raising the possibility that more anti-ligand and anti-
receptor monoclonal antibodies (mAbs) will show clinical
efﬁcacy. Indeed, mAbs to VEGFR-2, insulin-like growth factor
1 receptor (IGF1-R) and c-MET/HGF-R may enter clinical tests
in the near future (Ben-Kasus et al, 2007). Apparently, two
classes of molecular mechanisms enable mAbs to inhibit
cancer cell growth: immune mechanisms involving ANTI-
BODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC;
Clynes et al, 2000) and a variety of non-immune mechanisms
that intercept tumorigenesis, including triggering of mitochon-
dria-mediatedapoptosis,blockingangiogenesis,inhibitingcell
cycle progression, interfering with signaling cascades and
accelerating receptor internalization (Ben-Kasus et al, 2007).
Presumably, the combination of immune and other mechan-
isms presents uncommon perturbations that fail tumor
robustness. Remarkably, mAbs to RTKs are clinically used
primarily in combination with cytotoxic regimens. Thus,
combining trastuzumab with anthracyclins or taxanes
increases the average time to breast cancer progression,
both clinically approved antibodies to EGFR, cetuximab
and panitumumab, improve cytotoxicity of chemotherapy,
and the combination of cetuximab and radiotherapy reduces
mortality of patients with head and neck cancer (Bonner et al,
2006). Conceivably, the ability of mAbs to sensitize cancer
cells to cytotoxic drugs is a manifestation of the ability of
double interceptions to overcome network’s modularity.
Tyrosine kinase inhibitors
Low-molecular-weightcompounds that block theATP-binding
sites of RTKs present surprisingly high selectivity. Several
reversible inhibitors have already been approved (Table II),
and irreversible (covalent) inhibitors are in clinical develop-
ment. Among the approved drugs are Imatinib (Gleevec), an
inhibitor of BCR-ABL and c-KIT, approved for treatment of
leukemia and gastrointestinal spindle tumors, as well as two
EGFR inhibitors, geﬁtinib and erlotinib, approved for non-
small cell lung cancer. Likewise, sorafenib and sunitinib are
broader speciﬁcity compounds acting at VEGF receptors and
approved for advanced renal cell carcinoma (Carmeliet and
Jain, 2000). From a system’s perspective, the efﬁcacy of TKIs
targeting two or more RTKs (e.g., lapatinib) might be greater
than that of mono-speciﬁc drugs. Indeed, lapatinib, a dual
speciﬁcity inhibitor of EGFR and HER2, shows promising
results in clinical studies, in line with system’s fragilityagainst
simultaneous double hits, a rare event in evolution.
Acquired resistance to cancer therapy:
systems plasticity at work
In similarity to chemotherapy, the main challenge of targeted
therapy is drug resistance. For example, only one-third of
HER2-overexpressing mammary tumors respond to trastuzu-
mab (primary resistance), and patients who initially respond
to mAbs or to TKIs often relapse due to evolvement of
secondary resistance (Pao et al, 2005). The mechanisms
underlying resistance are poorly understood and they differ
between mAbs and TKIs (Hynes and Lane, 2005). The studies
we review below attribute acquired (secondary) drug resis-
tance to the remarkable ability of RTK networks to dynami-
cally switch their signaling circuitries.
Resistance to therapeutic mAbs
In contrast to patient response to Rituximab, an anti-CD20
mAb, which is affected by polymorphisms of Fc receptors
expressed on the surface of natural killer Tcells, resistance to
anti-RTK antibodies has not been associated with defects in
Table II Novel drugs targeting RTKs in human cancer
Molecular target Name of drug Description Cancer indication Approval status
(year of ﬁrst approval)
EGFR Cetuximab (Erbitux) Chimeric mAb CRC (with CT) Head and neck
(with RT)
Approved (2004)
Panitumumab (ABX-EGF) Human mAb CRC (with CT) Approved (2006)
Matuzumab (EMD 72000) Humanized mAb Lung cancer Phase II
Geﬁtinib (Iressa) TKI NSCLC Approved (2005)
Erlotinib (Tarceva) TKI NSCLC Pancreatic cancer (with CT) Approved (2004)
EGFR and HER2 Lapatinib (Tykerb) TKI Breast cancer (with CT) Approved (2007)
HER2 Trastuzumab (Herceptin) Humanized mAb Breast cancer (with CT) Approved (1998)
Pertuzumab (Omnitarg) Humanized mAb Ovarian cancer, breast cancer Phase II
MDX210 Bispeciﬁc antibody Ovarian cancer Phase III
Pan-HER/ERBB CI-1033 TKI NSCLC Phase II
EGFR, HER2, VEGFR AEE-788 TKI Glioblastoma Phase I
VEGFA Bevacizumab (Avastin) Humanized mAb CRC, NSCLC (with CT) Approved (2004)
VEGFR2 CDP791 Human F(ab)2 Lung cancer Phase II
VEGFR1-3, KIT, RET, PDGFRa Sunitinib (Sutent) TKI Renal cell carcinoma, GIST Approved (2006)
VEGFR2, KIT, PDGFRb, (RAF) Sorafenib (Nexavar) TKI Renal cell carcinoma Approved (2005)
HGFR XL880 TKI Solid tumors Phase I
KIT, PDGFR, (ABL) Imatinib (Glivec, Gleevec) TKI GIST Approved (2006)
Abbreviations: CT, chemotherapy; EGFR,epidermalgrowth factor receptor; HER2, human EGFR 2; GIST, gastrointestinal stromal tumor; mAb, monoclonal antibody; NSCLC,
non-small cell lung cancer; PDGFR, platelet-derived growth factor; RT, radiotherapy; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelialg r o w t hf a c t o rr e c e p t o r .
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steric hindrance of antigen–antibody interactions by a surface
glycoproteincalledMUC-4(Nagy etal,2005),seemtounderlie
part of patient resistance to trastuzumab, the most extensively
studied mAb (reviewed in Nahta and Esteva, 2006). Alter-
natively, the existence, or emergence, of compensatory
signaling pathways has been proposed, including paracrine
or autocrine loops involving an ERBB ligand capable of
stimulating alternative ERBB dimers (Valabrega et al, 2005).
Likewise, activationof a downstreamtargetof HER2 signaling,
such as mutational activation of RAS, B-RAF or the AKT-PI3K
pathway, which frequently occurs in solid tumor, may
circumvent pharmaceutical blocking of HER2. In this vein,
analysis of a small panel of HER2-overexpressing primary
breast tumors reported a correlation between patient response
to trastuzumab and expression levels of PTEN (Nagata et al,
2004). The IGF1-R shares with HER2 and EGFR the ability to
stimulate AKT and MAPK, and increased expression of this
receptor was shown to reduce trastuzumab-mediated growth
arrestofHER2-overexpressingbreastcancercells.Collectively,
these studies suggest that the PI3K–AKT pathway, stimulated
byeitherIGF1signalingorthroughPTENloss,offersanescape
route under treatment with mAbs.
Resistance to tyrosine kinase inhibitors
TwotypesofmechanismsappeartounderlieresistancetoTKIs.
The major one involves avoidance of drug-target interactions
andtheother likelyrelatestocompensatorysignalingpathways
(reviewed in Burgess and Sawyers, 2006). The ﬁrst reported
clinical resistance mutation, T351I, has been identiﬁed in BCR-
ABL (Gore et al, 2001). Overexpression of the wild-type target
kinase was found in a smaller fraction of resistant patients.
Along withthe identiﬁcationofadditionalresistance-conferring
mutations in BCR–ABL, similar alterations in EGFR, c-KITand
the PDGF-receptor were associated with clinical resistance of
non-small-cell lung cancer, gastrointestinal stromal tumors and
the hypereosinophilic syndrome to the respective TKIs. Active
efﬂux of imatinib, the most extensively studied TKI, as well as
compensatory activation of SRC family kinases, well character-
ized downstream effectors of BCR–ABL, have been implicated
in the resistance of the minority of imatinib-resistant patients,
who carry no kinase mutations. Last, according to a recent
study,resistanceofbreastcancerpatientstolapatinibinvolvesa
switchfromHER2andEGFRsignalingtodependencyonsteroid
hormone signaling (Xia et al, 2006), which reinforces the
primary role played by network adaptability in the acquisition
of drug resistance.
Conclusions and future directions
Universal laws govern a surprisingly broad spectrum of
complex systems, ranging from engineering and communica-
tion to business and society (Barabasi and Oltavi, 2004).
Complex biological systems, such as metabolism and signal
transductionobeythesegenerallawsasmeansthatimpartfail-
safe functioning (robustness; Stelling et al, 2004; Kitano,
2004a). Along with robustness andcommon design principles,
all complex systems evolved from signiﬁcantly simpler
modules (Kirschner and Gerhart, 1998). Our review has put
forward the notion that the evolutionary process of systems
growthandtrainingdisclosesfundamentalinformation,which
is not only vital for understanding systems’ logic, but can also
guide pharmaceutical intervention. Interestingly, although the
numbers of genes in the human and the nematode genomes
are comparable, the RTK family of mammals is fourfold larger
(Figure2).Further,byfollowingtheevolutionofasinglegroup
of RTKs, the ERBB/HER family, we infer a growth process that
utilized gene duplication and sub-functionalization to trans-
form a linear signaling cascade into a modular, richly
interconnected network.
In mammals, RTKs complement their predecessors, nuclear
hormone receptors, in multiple events of inductive cell lineage
determination. Several functional and architectural attributes
underlie the robust nature of RTK signaling, including an
intricate array of cytoplasmic and nuclear negative feedback
loops. Here we have concentrated on a recurring systems
controlmodule,namelyacompositefeedbackloopcomprising
a slow transcriptional arm coupled to a rapid protein–protein
interaction arm (Yeger-Lotem et al, 2004; Alon, 2006). In
similarity to other complex systems, the growth of the RTK
network necessitated the establishment of several highly
connected nodes (hubs), for example, the RTKs themselves,
RAS, RAF and PI3K. These hubs expose vulnerable points of
intervention: cancer-driving mutations, as well as pathogenic
viruses, frequently target the hubs, thereby locking the ‘ON’
state of the bistable system. An alternative locking device
occurring in human cancer comprises partial disabling of
multiple negative feedback loops (van Staveren et al, 2006;
Amit et al, 2007).
In-depth understanding of complex signaling systems, as
well as the tradeoffs of their robustness, will likely translate to
better management of diseases. In addition to identifying
critical hubs amenable for pharmacological interception,
systemslevelapproachespredictthatuncommoninterventions
would collapse the emergent robustness of oncogenic RTK
signaling(CarlsonandDoyle,2000).Therelativelyhighclinical
efﬁcacy of anti-receptor antibodies (Baselga, 2006) may be
regarded a successful uncommon perturbation involving
directed mobilization of the immune system. Likewise, the
broadly applicable replacement of the single-drug paradigm by
multi-component therapy is another reﬂection of systems
fragility against uncommon perturbations. In silico replicas of
RTK signaling, along with sophisticated high-throughput drug
discovery,are expected toidentify pointsoffragilityandreduce
drug toxicity. Moreover, because resistance to drugs is an
inevitable outcome of the ability of robust networks to switch
to compensatory signaling pathways, systems-inspired
dynamicRTKmodelingwillenableselectionofdrugcombinations
that can overcome secondary resistance in patients.
Acknowledgements
We thank Gabi Tarcic for critical comments and the RTK Consortium
for inspiration. Our laboratory is supported by research grants from
Dr Miriam and Sheldon G Adelson Medical Research Foundation,
the German Israel Foundation, the European Commission and the
National CancerInstitute. YY is the incumbent of the Harold and Zelda
Goldenberg Professorial Chair.
Evolvable signaling networks of receptor tyrosine kinases
I Amit et al
& 2007 EMBO and Nature Publishing Group Molecular Systems Biology 2007 11References
Alon U (2003)Biological networks: the tinkereras an engineer. Science
301: 1866–1867
Alon U (2006) An Introduction to Systems Biology: Design Principles of
Biological Circuits. Taylor and Francis: CRC Press
AmitI,CitriA,ShayT,LuY,KatzM,ZhangF,TarcicG,SiwakD,LahadJ,
Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G,
Alon U, Mills GB, Domany E, Yarden Y (2007) A module of negative
feedback regulators deﬁnes growth factor signaling. Nat Genet 39:
503–512
Aroian RV, Koga M, Mendel JE, Ohshima Y, Sternberg PW (1990) The
let-23 gene necessary for Caenorhabditis elegans vulval induction
encodes a tyrosine kinase of the EGF receptor subfamily. Nature
348: 693–699
Barabasi A-L, Oltavi ZN (2004) Network biology: understanding the
cell’s functional organization. Nat Rev Genet 5: 101–113
Barbasi A-L, Alberts R (1999) Emergence of scaling in random
networks. Science 286: 509–512
BaselgaJ(2006)Targetingtyrosinekinasesincancer:thesecondwave.
Science 312: 1175–1178
Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic
antibodies come of age: targeting minimal residual disease. Mol
Oncol 1: 42–54
Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature
411: 355–365
Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I,
Fischer S, Romeo G, Rossi B (1997) The multiple endocrine
neoplasia type 2B point mutation switches the speciﬁcity of the Ret
tyrosine kinase towards cellular substrates that are susceptible to
interact with Crk and Nck. Oncogene 15: 2257–2265
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones
CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J,
Youssouﬁan H, Amellal N, Rowinsky EK, Ang KK (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the
head and neck. N Engl J Med 354: 567–578
BosJL(1989)rasoncogenesinhumancancer:areview. CancerRes49:
4682–4689
Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR (2006)
Emerging roles of pseudokinases. Trends Cell Biol 16: 443–452
Bradham CA, Foltz KR, Beane WS, Arnone MI, Rizzo F, Coffman JA,
Mushegian A, Goel M, Morales J, Geneviere AM, Lapraz F,
Robertson AJ, Kelkar H, Loza-Coll M, Townley IK, Raisch M,
Roux MM, Lepage T, Gache C, McClay DR et al (2006) The sea
urchin kinome: a ﬁrst look. Dev Biol 300: 180–193
Burgess MR, Sawyers CL (2006) Treating imatinib-resistnat leukemia:
the next generation targeted therapies. ScientiﬁcWorldJournal 6:
918–930
Carballo E, Lai WS, Blackshear PJ (1998) Feedback inhibition of
macrophage tumor necrosis factor-alpha production by tristetraprolin.
Science 281: 1001–1005
CarlsonJM,DoyleJ(2000)Highlyoptimizedtolerance:robustnessand
design in complex systems. Phys Rev Lett 84: 2529–2532
CarmelietP, JainRK (2000) Angiogenesis incancerand otherdiseases.
Nature 407: 249–257
Casci T, Freeman M (1999) Control of EGF receptor signalling: lessons
from fruitﬂies. Cancer Metastasis Rev 18: 181–201
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc
receptors modulate in vivo cytoxicity against tumor targets. Nat
Med 6: 443–446
Courtneidge SA, Smith AE (1984) The complex of polyoma virus
middle-Tantigen and pp60c-src. EMBO J 3: 585–591
Csete M, Doyle J (2004) Bow-ties, metabolism and disease. Trends
Biotechnol 22: 446–450
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,
Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R,
Floyd Y,GrayK, HallS,HawesR, HughesJ,KosmidouV,MenziesA
et al (2002) Mutations of the BRAF gene in human cancer. Nature
417: 949–954
Dikic I, Giordano S (2003) Negative receptor signalling. Curr Opin Cell
Biol 15: 128–135
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A,
Schlessinger J, Waterﬁeld MD (1984) Close similarity of epidermal
growth factor receptor and v-erb-B oncogene protein sequences.
Nature 307: 521–527
Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP
(1991) Genes for epidermal growth factor receptor, transforming
growth factoralpha, and epidermal growthfactorand theirexpression
in human gliomas in vivo. Cancer Res 51: 2164–2172
Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K,
Sommergruber W, Kraut N, Ullrich A, Fassler R, Klein R (2006) Mig6
isanegativeregulatorofEGFreceptor-mediatedskinmorphogenesis
and tumor formation. Nat Med 12: 568–573
Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69
(Suppl 3): 11–16
Freeman M (2000) Feedback control of intercellular signalling in
development. Nature 408: 313–319
Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO,
Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC,
Burgess AW, Ward CW (2002) Crystal structure of a truncated
epidermal growth factor receptor extracellular domain bound to
transforming growth factor alpha. Cell 110: 763–773
Goldberg JM, Manning G, Liu A, Fey P, Pilcher KE, Xu Y, Smith JL
(2006) The dictyostelium kinome—analysis of the protein kinases
from a simple model organism. PLoS Genet 2: e38
Gore MF, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PM,
Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy
caused by BCR-ABL gene mutation or ampliﬁcation. Science 293:
876–880
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway III KL (1994)
Insect cell-expressed p180erbB3 possesses an impaired tyrosine
kinase activity. Proc Natl Acad Sci USA 91: 8132–8136
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:
57–70
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S,
Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G,
Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-
of-function mutations of c-kit in human gastrointestinal stromal
tumors. Science 279: 577–580
Hornberg JJ, Bruggman FJ, Westerhoff HV, Lankelma J (2006) Cancer:
a systems biology disease. BioSystems 83: 81–90
Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and
function. Annu Rev Biochem 69: 373–398
Hunter T (2000) Signaling—2000 and beyond. Cell 100: 113–127
Hynes NE, Lane HA (2005) ERBBreceptors and cancer: the complexity
of targeted inhibitors. Nat Rev Cancer 5: 341–354
Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F,
Lin SC, Gram H, Han J (2005) Involvement of microRNA in AU-rich
element-mediated mRNA instability. Cell 120: 623–634
Jones RB, Gordus A, Krall JA, Macbeath G (2006) A quantitative
protein interaction network for the ErbB receptors using protein
microarrays. Nature 439: 168–174
KholodenkoBN(2006)Cellsignallingdynamicsintimeandspace. Nat
Rev Mol Cell Biol 7: 165–176
Kirschner M, Gerhart J (1998) Evolvability. Proc Natl Acad Sci USA 95:
8420–8427
Kitano H (2004a) Biological robustness. Nat Rev Genet 5: 826–837
Kitano H (2004b) Cancer as a robust system: implications for
anticancer therapy. Nat Rev Cancer 4: 227–234
K l a p p e rL N ,G l a t h eS ,V a i s m a nN ,H y n e sN E ,A n d r e w sG C ,S e l aM ,
Yarden Y (1999) The ErbB-2/HER2 oncoprotein of human carcinomas
may function solely as a shared coreceptor for multiple stroma-
derived growth factors. Proc Natl Acad Sci USA 96: 4995–5000
Kolch W, Calder M, Gilbert D (2005) When kinases meet mathematics:
the systems biology of MAPK signalling. FEBS Lett 579: 1891–1895
Lanave C, Colangelo AM, Saccone C, Alberghina L (2007) Molecular
evolution of the neurotrophin family members and their Trk
receptors. Gene 394: 1–12
Evolvable signaling networks of receptor tyrosine kinases
I Amit et al
12 Molecular Systems Biology 2007 & 2007 EMBO and Nature Publishing GroupLau LF, Nathans D (1987) Expression of a set of growth-related
immediate early genes in BALB/c 3T3 cells: coordinate regulation
with c-fos or c-myc. Proc Natl Acad Sci USA 84: 1182–1186
Leveugle M, Prat K, Popovici C, Birnbaum D, Coulier F (2004)
Phylogenetic analysis of Ciona intestinalis gene superfamilies
supports the hypothesis of successive gene expansions. J Mol Evol
158: 168–181
Lynch M, Conery JS (2000) The evolutionaryfate and consequences of
duplicate genes. Science 290: 1151–1155
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA,
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG,
Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating
mutations in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to geﬁtinib. N Engl J
Med 350: 2129–2139
Marmor MD, Yarden Y (2004) Role of protein ubiquitylation in
regulating endocytosis of receptor tyrosine kinases. Oncogene 23:
2057–2070
Miyata T, Suga H (2001) Divergence pattern of animal gene families
and relationship with the Cambrian explosion. Bioessays 23:
1018–1027
Morrison DK, Murakami MS, Cleghon V (2000) Protein kinases and
phosphatases in the Drosophila genome. J Cell Biol 150: F57–F62
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P,
Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004)
PTEN activation contributes to tumor inhibition by trastuzumab,
and loss of PTEN predicts trastuzumab resistance in patients.
Cancer Cell 6: 117–127
Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J,
Jovin TM (2005) Decreased accessibility and lack of activation of
ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast
cancer cell line. Cancer Res 65: 473–482
Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of
trastuzumab resistance. Breast Cancer Res 8: 215–223
Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive
pathway map of eoidermal growth factor receptor signaling. Mol
Syst Biol 1: 2005.0010
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K,
Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal
structure of the complex of human epidermal growth factor and
receptor extracellular domains. Cell 110: 775–787
PaoW,MillerVA,PolitiKA,RieliGJ,SomwarR,ZakowskiMF,KrisMG,
Varmus H (2005) Acquired resistance of lung adenocarcinomas to
geﬁtinib or erlotinib is associated with a second mutation in the
EGFR kinase domain. PLoS Med 2: e73
Pastor-SatorrasR,SmithE,SoleRV(2003)Evolvingproteininteraction
networks through gene duplication. J Theor Biol 222: 199–210
Pires-daSilva A, Sommer RJ (2003) The evolution of signalling
pathways in animal development. Nat Rev Genet 4: 39–49
Rapp UR, Gotz R, Albert S (2006) BuCy RAFs drive cells into MEK
addiction. Cancer Cell 9: 9–12
Rzhetsky A, Gomez SM (2001) Birth of scale-free molecular networks
and the number of distinct DNA and protein domains per genome.
Bioinformatics 17: 988–996
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H,
Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S,
Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency
of mutations of the PIK3CA gene in human cancers. Science 304:
554
Sangster TA, Lindquist S, Queitsch C (2004) Under cover: causes,
effects and implications of Hsp90-mediated genetic capacitance.
Bioessays 26: 348–362
SantoroM,CarlomagnoF,RomanoA,BottaroDP,DathanNA,GriecoM,
Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995)
Activation of RET as a dominant transforming gene by germline
mutations of MEN2A and MEN2B. Science 267: 381–383
Santos SD, Verveer PJ, Bastiaens PI (2007) Growth factor-induced
MAPK network topology shapes Erk response determining PC-12
cell fate. Nat Cell Biol 9: 324–330
Sassone-Corsi P, Lamph WW, Verma IM (1988) Regulation of proto-
oncogene fos: a paradigm for early response genes. Cold Spring
Harb Symp Quant Biol 53 (Pt 2): 749–760
Satou Y, Sasakura Y, Yamada L, Imai KS, Satoh N, Degnan B (2003) A
genomewide survey of developmentally relevant genes in Ciona
intestinalis. V. Genes for receptor tyrosine kinase pathway and
Notch signaling pathway. Dev Genes Evol 213: 254–263
Schafer B, Gschwind A, Ullrich A (2004) Multiple G-protein-coupled
receptor signals converge on the epidermal growth factor receptor
to promote migration and invasion. Oncogene 23: 991–999
Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of
the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008
Shiu SH, Li WH (2004) Origins, lineage-speciﬁc expansions, and
multiple losses of tyrosine kinases in eukaryotes. Mol Biol Evol 21:
828–840
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL
(1987) Human breast cancer: correlation of relapse and survival
with ampliﬁcation of the HER-2/neu oncogene. Science 235:
177–182
Smolen P, Baxter DA, Byrne JH (2000) Mathematical modeling of gene
networks. Neuron 26: 567–580
Stein RA, Staros JV (2000) Evolutionary analysis of the ErbB receptor
and ligand families. J Mol Evol 50: 397–412
StellingJ,SauerU,SzallasiZ,DoyleIIIFJ,DoyleJ(2004)Robustnessof
cellular functions. Cell 118: 675–685
TanPB,KimSK(1999)Signalingspeciﬁcity:theRTK/RAS/MAPkinase
pathway in metazoans. Trends Genet 15: 145–149
Tautz D (2000) Evolution of transcriptional regulation. Curr Opin
Genet Dev 10: 575–579
Tsang M, Dawid IB (2004) Promotion and attenuation of FGF signaling
through the Ras–MAPK pathway. Sci STKE 228: pe17
Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G,
Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC,
Yarden Y (1998) Pathogenic poxviruses reveal viral strategies to
exploit the ErbB signaling network. EMBO J 17: 5948–5963
Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C,
Aglietta M, Comoglio PM, Giordano S (2005) TGFalpha expression
impairs trastuzumab-induced HER2 downregulation. Oncogene 24:
3002–3010
van Staveren WC, Solis DW, Delys L, Venet D, Cappello M, Andry G,
Dumont JE, Libert F, Detours V, Maenhaut C (2006) Gene
expression in human thyrocytes and autonomous adenomas
reveals suppression of negative feedbacks in tumorigenesis. Proc
Natl Acad Sci USA 103: 413–418
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they
control. Nat Med 10: 789–799
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S,
CarpenterG,GazdarAF,MuthuswamySK,ArteagaCL(2006)HER2
kinase domain mutation results in constitutive phosphorylation
and activation of HER2 and EGFR and resistance to EGFR tyrosine
kinase inhibitors. Cancer Cell 10: 25–38
Weinstein IB (2002) Addiction to oncogenes: the Achilles’ heal of
cancer. Science 297: 63–64
Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P,
Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM
(2004) Deubiquitination and ubiquitin ligase domains of A20
downregulate NF-kappaB signalling. Nature 430: 694–699
Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L,
Trusk P, Hill J, Harris J, Spector NL (2006) A model of acquired
autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a
therapeutic strategy to prevent its onset in breast cancer. Proc Natl
Acad Sci USA 103: 7795–7800
Xiong W, Ferrell Jr JE (2003) A positive-feedback-based bistable
‘memory module’ that governs a cell fate decision. Nature 426:
460–465
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling
network. Nat Rev Mol Cell Biol 2: 127–137
Yates PR, Atherton GT, Deed RW, Norton JD, Sharrocks AD (1999)
Id helix–loop–helix proteins inhibit nucleoprotein complex
Evolvable signaling networks of receptor tyrosine kinases
I Amit et al
& 2007 EMBO and Nature Publishing Group Molecular Systems Biology 2007 13formationbytheTCFETS-domaintranscriptionfactors.EMBOJ18:
968–976
Yeger-LotemY,SattathS,KashtanN,ItzkovitzS,MiloR,PinerRY,Alon
U, Magalit H (2004) Network motifs in integrated cellular networks
of transcription-regulation and protein–protein interaction. Proc
Natl Acad Sci USA 101: 5934–5999
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric
mechanism for activation of the kinase domain of epidermal
growth factor receptor. Cell 125: 1137–1149
ZhangY,Wolf-YadlinA,RossPL,PappinDJ,RushJ,LauffenburgerDA,
White FM (2005) Time-resolved mass spectrometry of tyrosine
phosphorylation sites in the epidermal growth factor receptor
signaling network reveals dynamic modules. Mol Cell Proteomics 4:
1240–1250
MolecularSystemsBiologyisanopen-accessjournal
publishedbyEuropeanMolecularBiologyOrganiza-
tion and Nature Publishing Group.
This article is licensed under a Creative Commons Attribution-
Noncommercial-Share Alike 3.0 Licence.
Evolvable signaling networks of receptor tyrosine kinases
I Amit et al
14 Molecular Systems Biology 2007 & 2007 EMBO and Nature Publishing Group